The paper “Efficacy and safety of boron neutron capture therapy for Hypopharyng……
Information
June 21st, 2024
Treatment results of unresectable, locally recurrent or locally advanced head and neck cancer published
A paper containing the treatment results of unresectable, locally recurrent or ……
December 25th, 2023
Orphan Drug designation for Borofalan (10B) (SPM-011) as treatment of Cutaneous Angiosarcoma
Angiosarcoma is a kind of cancer that is derived from vascular endothelial cell……
December 6th, 2023
Encounter with Director of Cancer Research Center of Lyon, and Team of Centre Léon Bérard at French Embassy
Business France Japan Office of the French Embassy in Japan engages in building……
On 25th September, the Groundbreaking Ceremony for the Boao BNCT center has tak……
September 27th, 2022
Stella Pharma Presented at Side Events of the 66th IAEA General Conference
The 66th International Atomic Energy Agency (IAEA) General Conference is being ……
April 7th, 2022
Stella Pharma Corporation was nominated as a finalist of the Informa Pharma Intelligence Awards Japan 2022
Informa Pharma Intelligence has announced that Stella Pharma is a nominee f……
February 18th, 2022
“Destroying Cancer with Boron and Neutrons” will be on NHK WORLD-JAPAN
Japan's public media organization NHK (Japan Broadcasting Corporation) will bro……
October 21st, 2021
Interview published on Science Japan, online magazine| Japan’s “Fifth Cancer Treatment,” BNCT, Finally Off the Ground
Here is a featured story on BNCT (Boron Neutron Capture Therapy) boron drug dev……
June 23rd, 2021
The phase II study of recurrent glioblastoma in Japan has published in “Neuro-Oncology Advances”
The title is “Accelerator-based BNCT for patients with recurrent glioblastoma: ……
December 9th, 2020
The phase II study of recurrent or locally advanced head and neck cancer in Japan has published in “Radiotherapy and Oncology”
The title is "Boron neutron capture therapy using cyclotron-based epithermal ne……
